Browse All

Current Filters

CLEAR FILTER x

TITLE

CSF Specific T Cell Activation Characterizes Neurological Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy

Author:Müller-Miny, Louisa   Haessner, Svea   Straeten, Frederike   Schulte-Mecklenbeck, Andreas   Wiendl, Heinz   Grauer, Oliver   Meyer zu Hörste, Gerd   

Session Name:S38: Autoimmune Neurology: Peripheral Autoimmunity, Paraneoplastic Disease, Checkpoint Inhibitors, and Neurosarcoidosis  

Topic:Autoimmune Neurology  

Program Number:S38.006  

Author Institution:University Hospital Münster, Münster, Germany  University of Muenster, Muenster, Germany  

Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Author:Leist, Thomas   Hauser, Stephen   Derfuss, Tobias   Wiendl, Heinz   Arnold, Douglas   Montalban, Xavier   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:S42: Multiple Sclerosis: Biomarkers/Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:S42.003  

Author Institution:Thomas Jefferson University, Philadelphia, PA, USA, Philadelphia, PA  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, Montreal, QC, Canada  Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland , Basel, Switzerland  Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany  

Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study

Author:Boer, Ibolya   Cree, Bruce   Wiendl, Heinz   Cross, Anne   Delgado, Sylvia   Habek, Mario   Khachanova, Natalia   Ward, Brian   Totolyan, Natalia   Mancione, Linda   Sullivan, Roseanne   Zielman, Ronald   Hu, Xixi   Das Gupta, Ayan   Montalban, Xavier   Winthrop, Kevin   

Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1  

Topic:Multiple Sclerosis  

Program Number:P1.010  

Author Institution:Novartis Pharma AG, Basel, Switzerland  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Washington University School of Medicine, Saint Louis, MO  University of Miami Miller School of Medicine, Miami, FL  University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia  Pirogov Russian National Research Medical University, Moscow, Russian Federation  Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada  First Saint Petersburg State Medical University, St Petersburg , Russian Federation  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V, Amsterdam, Netherlands  Novartis Healthcare Private Limited, Hyderabad, India  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  School of Public Health at Oregon Health & Science University, Portland, OR  

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials

Author:Cross, Anne   Ziemssen, Tjalf   Arnold, Douglas   Thouvenot, Eric   Zamvil, Scott   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Wiendl, Heinz   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.011  

Author Institution:Washington University School of Medicine, Saint Louis, MO, USA, Saint Louis, MO  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany, Dresden, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Centre Hospitalier Universitaire (CHU) Nîmes, University of Montpellier, Nîmes, France  Institut de Génomique Fonctionnelle, UMR, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Montpellier, Montpellier, France, Nimes Cedex 9, France  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA, San Francisco, CA  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO, USA, Aurora, CO  University of Münster, Münster, Germany, Muenster, Germany  

Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis

Author:Kieseier, Bernd   Montalban, Xavier   Williams, Mitzi   Airas, Laura   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Doerner, Thomas   Loop, Brett   DeLasHeras, Virginia   Willi, Roman   Haemmerle, Sibylle   Zharkov, Artem   Barbier, Nathalie   Azmon, Amin   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Gimenez-Arnau, Ana   Chitnis, Tanuja   

Session Name:P8: Multiple Sclerosis: Non-MS CNS Neuroinflammatory Diseases and Progressive MS and Remyelination/Neuroprotection  

Topic:Multiple Sclerosis  

Program Number:P8.015  

Author Institution:Novartis Pharma AG, Basel, Switzerland  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  Joi Life Wellness Group, Atlanta, GA  Turku University Hospital and University of Turku, Turku, Finland  Johns Hopkins Asthma and Allergy Center, Baltimore, MD  Hiroshima Citizens Hospital, Minami-ku, Japan  University of Toronto, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite – Universitätsmedizin Berlin, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA  Novartis Institutes for Biomedical Research, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Urticaria Center of Reference and Excellence, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany  Department of Dermatology, Hospital del Mar – IMIM, Universitat Pompeu Fabra, Barcelona, Spain  Department of Neurology, Brigham and Women's Hospital, Boston, MA